Novo Nordisk breaks ground on $2 billion production facility in Clayton, North Carolina
The facility will produce APIs for a range of Novo Nordisk's current and future GLP-1 and insulin products.
Novo Nordisk has broken ground on its new 2 billion US dollar production facility in Clayton, North Carolina.
The facility will produce active pharmaceutical ingredients (API) for a range of Novo Nordisk's current and future GLP-1 and insulin products. Once fully operational in 2020, Clayton will ensure production capacity for diabetes care products in the US for the decade ahead.
"As the prevalence of diabetes has grown in the US, so too has the demand for effective treatments," said Lars Rebien Sørensen, president and CEO of Novo Nordisk. "It gives me great pride to break ground on our new facility site in Clayton where we have an existing, strong organisation. This site will play a vital role in enabling us to meet the needs of people living with diabetes in the US for years to come."
The new site is situated adjacent to Novo Nordisk's existing 42,000 m2 facility, which assembles and packages FlexPen and FlexTouch prefilled insulin devices for the US market. The expansion is expected to create close to 700 new jobs and Novo Nordisk expects to create a significant employment effect during the construction period with up to 2,500 people working on the project at its peak.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.